Completed PHASE1 INTERVENTIONAL 1-arm NCT02437539

Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography (uPAR-PET)

68Ga-NOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor), for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Human

Sponsor: Curasight

Conditions Breast Cancer Prostate Cancer Urinary Bladder Cancer

Interventions Injection of 68Ga-NOTA-AE105 Positron Emission Tomography scans

Updated 5 times since 2017 Last updated: Aug 21, 2015 Started: May 31, 2015 Primary completion: Aug 31, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Breast Cancer and Prostate Cancer and is currently completed. Curasight leads this study, which shows 5 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Curasight
Rigshospitalet, Denmark

Data source: Rigshospitalet, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark